187 related articles for article (PubMed ID: 37318556)
1. [Statin intolerance-Statin tolerance].
Vogt A
Inn Med (Heidelb); 2023 Jul; 64(7):622-628. PubMed ID: 37318556
[TBL] [Abstract][Full Text] [Related]
2. [Statin intolerance and statin-associated muscular pain].
Stürzebecher PE; Schumann F; Kassner U; Laufs U
Herz; 2022 Jun; 47(3):204-211. PubMed ID: 35451596
[TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
4. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials.
Laufs U; Ballantyne CM; Banach M; Bays H; Catapano AL; Duell PB; Goldberg AC; Gotto AM; Leiter LA; Ray KK; Bloedon LT; MacDougall D; Zhang Y; Mancini GBJ
J Clin Lipidol; 2022; 16(3):286-297. PubMed ID: 35346603
[TBL] [Abstract][Full Text] [Related]
6. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
7. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.
Thompson PD; MacDougall DE; Newton RS; Margulies JR; Hanselman JC; Orloff DG; McKenney JM; Ballantyne CM
J Clin Lipidol; 2016; 10(3):556-67. PubMed ID: 27206943
[TBL] [Abstract][Full Text] [Related]
8. Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management.
Iatan I; Mancini GBJ; Yeoh E; Hegele RA
Expert Rev Cardiovasc Ther; 2023 Jun; 21(6):423-435. PubMed ID: 37212306
[TBL] [Abstract][Full Text] [Related]
9. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance.
Thompson PD; Rubino J; Janik MJ; MacDougall DE; McBride SJ; Margulies JR; Newton RS
J Clin Lipidol; 2015; 9(3):295-304. PubMed ID: 26073387
[TBL] [Abstract][Full Text] [Related]
10. Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
Sivashanmugarajah A; Fulcher J; Sullivan D; Elam M; Jenkins A; Keech A
Intern Med J; 2019 Sep; 49(9):1081-1091. PubMed ID: 31507054
[TBL] [Abstract][Full Text] [Related]
11. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
12. Advances in the management of statin myopathy.
Gallo A; Perregaux J; Bruckert E
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):142-151. PubMed ID: 33278129
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
[TBL] [Abstract][Full Text] [Related]
14. Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
Rosenson RS; Baker S; Banach M; Borow KM; Braun LT; Bruckert E; Brunham LR; Catapano AL; Elam MB; Mancini GBJ; Moriarty PM; Morris PB; Muntner P; Ray KK; Stroes ES; Taylor BA; Taylor VH; Watts GF; Thompson PD
J Am Coll Cardiol; 2017 Sep; 70(10):1290-1301. PubMed ID: 28859793
[TBL] [Abstract][Full Text] [Related]
15. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
16. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
Pedersen TR
Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
[TBL] [Abstract][Full Text] [Related]
18. Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions.
Penson PE; Mancini GBJ; Toth PP; Martin SS; Watts GF; Sahebkar A; Mikhailidis DP; Banach M;
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1023-1033. PubMed ID: 30311434
[TBL] [Abstract][Full Text] [Related]
19. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.
Alla VM; Agrawal V; DeNazareth A; Mohiuddin S; Ravilla S; Rendell M
Drugs; 2013 Jul; 73(10):1025-54. PubMed ID: 23754124
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
